Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
38.46 USD | -0.88% | -4.66% | -16.50% |
Financials (USD)
Sales 2024 * | 1.76M | Sales 2025 * | 8.84M | Capitalization | 2.9B |
---|---|---|---|---|---|
Net income 2024 * | -221M | Net income 2025 * | -262M | EV / Sales 2024 * | 1,233 x |
Net cash position 2024 * | 727M | Net cash position 2025 * | 650M | EV / Sales 2025 * | 255 x |
P/E ratio 2024 * |
-13.2
x | P/E ratio 2025 * |
-11.8
x | Employees | 255 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.44% |
Latest transcript on Xenon Pharmaceuticals Inc.
1 day | -0.88% | ||
1 week | -4.66% | ||
Current month | -5.39% | ||
1 month | -6.40% | ||
3 months | -22.24% | ||
6 months | +33.87% | ||
Current year | -16.50% |
Managers | Title | Age | Since |
---|---|---|---|
Ian Mortimer
CEO | Chief Executive Officer | 48 | 13-10-20 |
Simon Pimstone
FOU | Founder | 56 | 96-11-04 |
Sherry Aulin
DFI | Director of Finance/CFO | 40 | 10-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Clarence Machado
BRD | Director/Board Member | 60 | 20-11-04 |
Mohammad Azab
BRD | Director/Board Member | 68 | 03-09-30 |
Justin Gover
BRD | Director/Board Member | 53 | 23-08-07 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.96% | 14 M€ | -3.15% | ||
0.22% | 0 M€ | 0.00% | - | |
0.22% | 0 M€ | 0.00% | - | |
0.20% | 12 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-23 | 38.46 | -0.88% | 591,856 |
24-05-22 | 38.8 | -0.46% | 418,657 |
24-05-21 | 38.98 | -3.56% | 359,807 |
24-05-20 | 40.42 | +1.56% | 469,380 |
24-05-17 | 39.8 | -1.34% | 261,461 |
Delayed Quote Nasdaq, May 23, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.50% | 2.9B | |
+10.79% | 116B | |
+11.65% | 106B | |
-6.20% | 23.89B | |
-2.33% | 21.58B | |
-6.03% | 18.96B | |
-13.41% | 16.33B | |
-40.50% | 16.96B | |
+6.64% | 14.14B | |
+31.84% | 12.02B |
- Stock Market
- Equities
- XENE Stock